Stem cell therapy success rate: what does the number mean?

What does a success rate leave out?

A clinic's percentage may not say how much people improved or how long relief lasted. It may also miss people who never returned to report a result.

Joints have better and worse weeks, and many people seek care during a bad one. Later improvement can make a treatment look more helpful than it was.

A useful study follows two similar groups for the same length of time. One group gets the treatment, while the other gets different care. The difference between them gives a better estimate of what the treatment did.

What do fair comparisons show?

Studies have compared joint treatments made from bone marrow, fat, or cord tissue with a steroid treatment. Each group often reported less soreness, though the research doesn't tell us who will feel relief.

At QC Kinetix, regenerative treatments are clinic procedures that place material prepared from your body into the sore joint. A medical provider examines you before discussing a choice, but that title doesn't always mean doctor. Ask about the examiner's license.

No clinic percentage can promise your result.

Which result matters in daily life?

Choose one task before care begins. You might track standing from a chair, walking to the mailbox, or waking less often at night.

Write down how far you can go and how sore you feel later. Check the same task after treatment at the time the clinic recommends.

The result won't prove why you improved, but it will show whether soreness fell or the chosen task became easier. That is useful to know.

Sources

1. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.

2. A meta-analysis of 14 placebo cohorts across 13 Level I trials in 1,076 knee osteoarthritis patients found that intra-articular saline - the placebo - produced pain and function improvements exceeding the minimal clinically important difference at 3 and 6 months.

   Saltzman BM, et al. — The Therapeutic Effect of Intra-articular Normal Saline Injections for Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies. Am J Sports Med, 2017. DOI: 10.1177/0363546516680607.

3. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

4. A 2023 appraisal of 15 randomized and 11 non-randomized trials of culture-expanded MSCs for knee osteoarthritis found function improved relative to control in 11 of 15 RCTs and cartilage protection or repair reported in 18 of 21 imaging studies, but noted the total sample of 610 patients limits any definitive conclusion.

   Copp G, et al. — Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success. Cell Mol Immunol, 2023. DOI: 10.1038/s41423-023-01020-1.

5. A network meta-analysis of 79 randomized trials in 8,761 patients ranked the intra-articular injectables for knee osteoarthritis on VAS and WOMAC at 1, 3, 6 and 12 months, placing the cell-based options within a crowded field rather than above it.

   Anil U, et al. — The efficacy of intra-articular injections in the treatment of knee osteoarthritis: A network meta-analysis of randomized controlled trials. Knee, 2021. DOI: 10.1016/j.knee.2021.08.008.

6. A 2025 systematic review and meta-analysis of 8 randomized trials in 502 patients found intra-articular mesenchymal stem cells improved WOMAC scores versus control at 6 months (MD 7.44, 95% CI 1.45-13.42) and 12 months (MD 10.31, 95% CI 0.96-19.67), with wide confidence intervals and a small pooled sample.

   Cao M, et al. — Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther, 2025. DOI: 10.1186/s13287-025-04252-2.